Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Capecitabine|DRUG: Neratinib|BEHAVIORAL: EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Puma Biotechnology, Inc.